Not a good buy right now: no proprietary buy signal, weak/negative profitability trends, and no near-term catalysts.
Price is sitting below the pivot (1.727) with only a modest technical edge; downside risk remains to S1 (1.501).
Options positioning shows heavier put open interest (bearish/defensive) alongside extremely high implied volatility, which is not attractive for an impatient long entry.
Flows are not supportive: hedge funds and insiders are neutral; no politician activity to validate conviction.
Trend/structure: mixed-to-weak; price is below Pivot 1.727, with overhead resistance at R1 1.952 and R2 2.091.
Momentum: MACD histogram is positive (0.0287) but contracting, implying bullish momentum is fading rather than strengthening.
RSI(6) at 38.89: near the lower end of neutral, leaning weak (not an oversold bounce signal).
Moving averages: converging, consistent with consolidation and lack of a clean trend.
Key levels to watch: Support S1 1.501 then S2 1.362; a reclaim of 1.727 improves odds of a move toward 1.95.
Pattern-based forward odds (provided): ~80% chance of -0.32% next day, +1.96% next week, -1.35% next month → not compelling for an immediate buy.
Options Data
Bearish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio
Positioning: Put open interest 225 vs call open interest 125 → OI put/call 1.8 suggests more downside hedging/bearish bias.
Activity/liquidity: Very low call volume (0) and small put volume (20) → sentiment read is noisy due to thin trading.
Volatility: 30D IV ~406% (IV percentile 75.4) vs historical vol ~61% → options are pricing extreme move risk; for a stock buy, this typically signals uncertainty rather than a clean bullish setup.
Today’s volume vs 30D avg shows a spike (500% of avg), but it’s off a small base, so conviction is limited.
Technical Summary
Sell
9
Buy
5
Positive Catalysts
and holds, technical upside toward 1.95 becomes more plausible.
Neutral/Negative Catalysts
No news in the recent week: lack of identifiable near-term catalyst to justify an impatient entry.
Profitability deterioration in 2025/Q3: net loss widened YoY and gross margin is deeply negative.
Options open interest skew is bearish/defensive (put-heavy).
Thinly traded options (and likely thin underlying liquidity) can amplify downside air pockets.
No supportive signaling from hedge funds/insiders (both neutral) and no congress trading data indicating influential accumulation.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: $77K, +1825% YoY (strong growth rate, but absolute revenue remains very small).
Net income: -$3.483M, -19.49% YoY (loss widened).
EPS: -$0.27, -28.95% YoY (worsened).
Gross margin: -249.35 (deeply negative), -96.28% YoY → unit economics/expenses still a major headwind.
Overall: growth exists, but fundamentals are not yet improving in a way that typically supports a durable near-term uptrend.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating/price target change data was provided, so there is no observable recent trend in upgrades/downgrades or target revisions.
Wall Street pro view (based on available data):
Pros: early-stage revenue acceleration could be a setup if partnerships/product milestones materialize.
Cons: ongoing losses, negative margins, and lack of near-term catalysts make the risk/reward unattractive for buying immediately.
Wall Street analysts forecast CLGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLGN is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast CLGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLGN is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Buy
Hold
Sell
0
Current: 0.750
Low
0
Averages
0
High
0
0
Current: 0.750
Low
0
Averages
0
High
0
D. Boral Capital
Jason Kolbert
Buy
to
Hold
downgrade
AI Analysis
2026-02-06
New
Reason
D. Boral Capital
Jason Kolbert
Price Target
AI Analysis
2026-02-06
New
downgrade
Buy
to
Hold
Reason
D. Boral Capital analyst Jason Kolbert downgraded CollPlant to Hold from Buy with no price target. The company's recently announced $2M registered direct financing appears to have triggered a "disproportionate response," raising investors concerns, the analyst says.
